Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Community Doctor's Perspective on Sickle Cell Disease & Voxelotor's Potential (GBT440)

Ticker(s): GBT

Who's the expert?

Name: Dr Mamta Vijayvargiya - MD

  • Hematologist at Osceola Cancer Center in FL and in private practice.
  • Currently manages 25 patients with sickle cell and attended ASH 2019.
  • Board certified in both medical oncology and hematology; member of the American Society of Clinical Oncology, the American Society of Hematology and the American College of physicians.

Interview Questions
Q1.

Please describe your clinical practice; how many patients with sickle cell disease do you currently manage?

Added By: c_admin
Q2.

What % of your patients would be good candidates for voxeletor?

Added By: c_admin
Q3.

What is your perspective with regard to patient compliance? What have you seen by way of compliance with the current standard of care?

Added By: gkiernan
Q4.

Do you view the recently approved Novartis compound as complementary or competitive with voxeletor?

Added By: gkiernan

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.